two among them) have permitted the identification of factors that predict coronary events in initially asymptomatic individuals. These studies have contributed to our current understanding of the importance of variables, such as age, diabetes, hypertension, smoking, and of plasma lipid markers (such as LDL-cholesterol and HDL-cholesterol) in risk assessment. 1, 2 Although several lipid-lowering trials have clearly established the importance of targeting LDLcholesterol in order to reduce the risk of a first or recurrent coronary heart disease (CHD) event, [3] [4] [5] [6] [7] [8] [9] it has become evident that the relative risk reduction achieved by lipid-lowering therapy only reached about 30%, a finding that clearly indicates that high-risk individuals treated with lipid-lowering drugs do remain at high absolute risk for a first or recurrent CHD event. Furthermore, a substantial proportion of CHD patients do not have LDL-cholesterol levels that are different from the healthy asymptomatic population, 10, 11 suggesting that there is a need to go beyond the lipid hypothesis and classical risk factors in order to properly assess and manage a significant proportion of high-risk individuals if we aim at achieving optimal clinical benefits. In accordance with this notion, there is increased recognition that the individual's risk is determined by the additive/synergistic contribution of risk factors. 12, 13 In this regard, several studies have suggested that additional variables could predict CHD events beyond classical risk factors. [14] [15] [16] [17] [18] [19] Thus, CHD risk is determined by a complex interplay between additional metabolic abnormalities modulating the probabilities of an acute coronary syndrome. For instance, as discussed by Tracy 20 in this symposium, there is considerable evidence from prospective observational studies that variables reflecting inflammation are also useful in the prediction of acute coronary events both in patients with documented CHD or in asymptomatic individuals. 21 Among these new markers, the most popular by far has been the plasma C-reactive protein (CRP) concentration. With the development of sensitive assays, Ridker and co-workers 21 have largely contributed to a rapidly flourishing literature, which has suggested that an elevated CRP concentration was predictive of the risk of myocardial infraction, stroke, peripheral arterial disease and sudden death. Furthermore, it has also been suggested that CRP could predict events beyond classical risk factors used in risk assessment, including the plasma lipid profile. 22 The production of CRP by the liver is under the control of cytokines which are elevated in acute infection states. 23 However, in the context of the present symposium and considering the current epidemic proportions reached by diabetes and obesity worldwide, Yudkin 24 has proposed that the expanded adipose depot could, in overweight and obese patients, represent an important source of cytokine production, which would in turn stimulate hepatic CRP production. He provided evidence that adipose tissue is a significant site of interleukin (IL)-6 and of tumor necrosis factor (TNF)-a production, which could both stimulate CRP production by the liver. Thus, with the highly prevalent metabolic syndrome resulting from the fact that a substantial proportion of our population is in positive energy balance, the following question remains: would the relationship between CRP concentration and coronary events remain significant if proper control was made for the concomitant variation in abdominal adipose tissue mass? At this stage, it is important to mention that most studies have failed to properly control for abdominal fat accumulation when reporting the apparently independent association between CRP and the risk of myocardial infarction. Even the recent report by Ridker et al 25 suggesting that CRP concentration could predict further CHD events beyond the features of the metabolic syndrome, had the caveat that abdominal fat accumulation was not measured (nor was at least waist circumference as a crude marker of abdominal fat). Of course, there are other sources of elevated plasma CRP, but we do not know whether all causes of elevated CRP are equally predictive of an increased CHD risk. On the basis of a rapidly expanding literature suggesting a direct effect of CRP on vascular wall biology, 26, 27 it is very likely that CRP will emerge as a convenient marker of CHD risk beyond classical risk factors. 26 However, we would like to propose that the most prevalent cause of elevated plasma CRP concentration in our affluent sedentary population exposed to a surplus of dietary energy is abdominal obesity 28 ( Figure 1 ). In addition, a recent report has revealed that CRP mRNA is expressed in human adipose tissue and that a strong inverse relationship is found between the CRP and adiponectin mRNA levels in human adipose tissue. 29 Thus, further studies are clearly warranted to verify whether an elevated CRP resulting from an insulin resistant 'dysmetabolic milieu' (and therefore accompanied by altered IL-6, TNF-a and adiponectin levels) has the same relative impact on CHD risk than when it results from other insults in the nonobese, physically active segment of our population. It will also be clinically relevant to verify whether the presence of abdominal obesity exacerbates the inflammatory response to various environmental stimuli. Finally, irrespective of the independent contribution of CRP to the etiology of CHD events, the inflammatory component of CHD opens the search for additional therapeutic targets beyond the management of the atherogenic dyslipidemia. As nicely review by Staels and co-workers 30 Further work is clearly needed in this area, but there is compelling evidence that the macrophage also represents an interesting target for the management of CHD risk. In summary, it is now well accepted that CHD has an inflammatory component and that its related markers predict acute coronary events. Further studies are, however, needed to identify the primary factors involved in the inflammatory profile found among high-risk abdominally obese patients with elevated CRP concentrations to identify the most clinically relevant target(s) in this population. processes involved in the etiology of CHD. Second, an elevated CRP concentration may reflect a 'cytokine attack' that could have an impact on several cell types involved in plaque proliferation, stability, etc. Finally, an elevated CRP concentration may also be a marker of an atherogenic, insulin resistant 'dysmetabolic milieu', which is known to increase CHD risk beyond the contribution of classical risk factors. It is proposed that the increased CHD risk attributed to elevated CRP concentrations is explained by the synergistic contribution and possibly interaction of all above factors.
